JP2015504073A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504073A5
JP2015504073A5 JP2014551387A JP2014551387A JP2015504073A5 JP 2015504073 A5 JP2015504073 A5 JP 2015504073A5 JP 2014551387 A JP2014551387 A JP 2014551387A JP 2014551387 A JP2014551387 A JP 2014551387A JP 2015504073 A5 JP2015504073 A5 JP 2015504073A5
Authority
JP
Japan
Prior art keywords
peptide
composition
amino acid
medicament
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014551387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504073A (ja
JP6416627B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/020498 external-priority patent/WO2013106273A2/en
Publication of JP2015504073A publication Critical patent/JP2015504073A/ja
Publication of JP2015504073A5 publication Critical patent/JP2015504073A5/ja
Application granted granted Critical
Publication of JP6416627B2 publication Critical patent/JP6416627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014551387A 2012-01-09 2013-01-07 ペプチドおよびその使用法 Active JP6416627B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261584517P 2012-01-09 2012-01-09
US61/584,517 2012-01-09
US201261699571P 2012-09-11 2012-09-11
US61/699,571 2012-09-11
PCT/US2013/020498 WO2013106273A2 (en) 2012-01-09 2013-01-07 Peptides and methods of using same

Publications (3)

Publication Number Publication Date
JP2015504073A JP2015504073A (ja) 2015-02-05
JP2015504073A5 true JP2015504073A5 (cg-RX-API-DMAC7.html) 2016-02-25
JP6416627B2 JP6416627B2 (ja) 2018-10-31

Family

ID=47595077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551387A Active JP6416627B2 (ja) 2012-01-09 2013-01-07 ペプチドおよびその使用法

Country Status (10)

Country Link
US (6) US9951104B2 (cg-RX-API-DMAC7.html)
EP (2) EP3381461B1 (cg-RX-API-DMAC7.html)
JP (1) JP6416627B2 (cg-RX-API-DMAC7.html)
AU (3) AU2013208293B2 (cg-RX-API-DMAC7.html)
CA (2) CA2859777C (cg-RX-API-DMAC7.html)
DK (2) DK3381461T3 (cg-RX-API-DMAC7.html)
ES (2) ES2871544T3 (cg-RX-API-DMAC7.html)
IL (1) IL233481A0 (cg-RX-API-DMAC7.html)
MX (1) MX365403B (cg-RX-API-DMAC7.html)
WO (1) WO2013106273A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3381461T3 (da) 2012-01-09 2021-05-17 Serpin Pharma Llc Peptider og fremgangsmåder til anvendelse deraf
WO2014197524A2 (en) * 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
US20160194365A1 (en) 2013-07-08 2016-07-07 The University Of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders
CA2961375A1 (en) * 2014-09-16 2016-03-24 Bioincept, Llc Compositions and methods for treating acute radiation syndrome
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20160256611A1 (en) * 2015-03-04 2016-09-08 Microvention, Inc. Drug Delivery Device
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA2996975C (en) * 2015-08-28 2022-02-15 Serpin Pharma, Llc Methods for treatment of diseases
WO2017083433A1 (en) * 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3789491B1 (en) 2018-05-02 2025-04-16 Kansai Medical University Educational Corporation Peptide and use therefor
WO2022010939A2 (en) * 2020-07-06 2022-01-13 Serpin Pharma, Llc Peptides and methods of using the same

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
FI81498C (fi) 1987-01-13 1990-11-12 Biocon Oy Kirurgiska material och instrument.
US5580561A (en) * 1987-03-06 1996-12-03 Cercek; Boris Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
US5270171A (en) * 1987-03-06 1993-12-14 Boris Cercek Cancer-associated SCM-recognition factor, preparation and method of use
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
CA2143823C (en) 1992-08-27 2005-07-26 Alfio Comis Retro-, inverso - and retro-inverso synthetic peptide analogues
EP1132080A3 (en) 1992-09-10 2001-10-17 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
CA2234931C (en) 1995-10-16 2010-01-19 Dana-Farber Cancer Institute Novel expression vectors and methods of use
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2219011T3 (es) 1998-04-24 2004-11-16 University Of Florida Vector viral adeno-asociado recombinante que codifica alfa-1 antitripsina para terapia genica.
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
US20070003518A1 (en) 2002-04-19 2007-01-04 Atkinson Mark A Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
ES2622522T3 (es) 2003-08-26 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad proteasa de serina y su uso en métodos y composiciones para el tratamiento de infecciones bacterianas
JP2007517913A (ja) 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド カルシトニン遺伝子関連ペプチドを投与することによって急性心筋梗塞を処置するための方法およびカルシトニン遺伝子関連ペプチドを含有する組成物
DK1766412T3 (da) * 2004-05-21 2009-05-25 Inst Systems Biology Sammensætninger og fremgangsmåder til kvantificering af serumglycoproteiner
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
WO2007070981A1 (en) 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
US20110191871A1 (en) 2006-02-28 2011-08-04 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
US20090203602A1 (en) * 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2008033890A2 (en) 2006-09-12 2008-03-20 Beth Israel Deaconess Medical Center, Inc. Compositions containing alpha-1-antitrypsin and methods for use
EA201000399A1 (ru) 2007-08-30 2011-02-28 Кьюрдм, Инк. Композиции и способы использования проостровковых пептидов и их аналогов
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US7923253B2 (en) * 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
US9522179B2 (en) 2010-03-04 2016-12-20 Virginia Commonwealth University Compositions and methods for modulating cardiac conditions
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
WO2011139368A2 (en) 2010-05-06 2011-11-10 The Feinstein Institute For Medical Research Methods of treatment of inflammatory diseases
DK3381461T3 (da) 2012-01-09 2021-05-17 Serpin Pharma Llc Peptider og fremgangsmåder til anvendelse deraf
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2014197524A2 (en) 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
KR20160146242A (ko) 2015-06-12 2016-12-21 현대자동차주식회사 터보차저 엔진의 재순환 밸브 구동 장치 및 방법
CA2996975C (en) 2015-08-28 2022-02-15 Serpin Pharma, Llc Methods for treatment of diseases

Similar Documents

Publication Publication Date Title
JP2015504073A5 (cg-RX-API-DMAC7.html)
Verstockt et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
JP2018162295A (ja) 医薬製剤
Kamei et al. Determination of the optimal cell-penetrating peptide sequence for intestinal insulin delivery based on molecular orbital analysis with self-organizing maps
US20130281377A1 (en) Treating multiple myeloma
KR20100020516A (ko) Ｇｌｐ-1-ｆｃ 융합 단백질 제제
EA025663B1 (ru) Композиции этанерцепта, стабилизированные ионами металлов
JP2019533722A5 (cg-RX-API-DMAC7.html)
CN1812808A (zh) 稳定化的药物肽组合物
JP2014513952A5 (cg-RX-API-DMAC7.html)
Henry et al. Efficacy of anti hyperglycemic therapies and the influence of baseline hemoglobin A1C: a meta-analysis of the liraglutide development program
JP2025511080A (ja) 製剤化方法
Galipeau Mesenchymal stromal cells for graft-versus-host disease: a trilogy
Prachayakul et al. Factors influencing clinical outcomes of Histoacryl® glue injection-treated gastric variceal hemorrhage
Ding et al. Hemodynamic effects of continuous versus bolus infusion of terlipressin for portal hypertension: a randomized comparison
JP2019520316A5 (cg-RX-API-DMAC7.html)
JP2015508771A5 (cg-RX-API-DMAC7.html)
JP2020502150A5 (cg-RX-API-DMAC7.html)
JP2020502140A5 (cg-RX-API-DMAC7.html)
CN110650747A (zh) 用于治疗慢性肾病的杜拉鲁肽
JP2017500316A5 (cg-RX-API-DMAC7.html)
Son et al. SAMiRNA targeting amphiregulin alleviate total-body-irradiation-induced renal fibrosis
Dauvergne et al. Renal diseases secondary to interferon-β treatment: a multicentre clinico-pathological study and systematic literature review
Olivotto et al. INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
JP2014519514A5 (cg-RX-API-DMAC7.html)